dm+d
407031006
Medicine Compliance Aid Stability
VesicareAstellas Pharma Ltd
Astellas Pharma Ltd
Vesicare
Tablets f/c 5mg, 10mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
25 October 2022
Lactation Safety Information
Oxybutynin
No published evidence of safety
Low levels anticipated in milk due to the drug’s properties although very long half-life increases risk of accumulation in breastfed infants
Monitor infant for anticholinergic effects, e.g. urinary retention, colic and constipation
18 September 2020